A Randomised, Single Centre, Double-Blind, Incomplete Block Trial to Test for Equivalence Between Subcutaneous Injections of the GLP-1 Analogue NN9535 in 1 mg/ml, 3 mg/ml and 10 mg/ml Concentrations in Healthy Male Subject.
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2015
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 30 Apr 2009 Actual patient number (44) added as reported by ClinicalTrials.gov.
- 30 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.